| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
13,030,000 |
| Market
Cap: |
51.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.34 - $22.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 634 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Eagle Pharmaceuticals is a pharmaceutical company focused on developing medicines to treat diseases of the central nervous system or metabolic critical care therapeutic areas as well as in oncology. Co.'s products include: Belrapzo® (bendamustine ready-to-dilute (RTD) 500ml solution), Bendeka® (infused bendamustine RTD) and Treakisym® for chronic lymphocytic leukemia and non-hodgkin's lymphoma; Ryanodex® (dantrolene sodium) for malignant hyperthermia; EP-4104 Ryanodex® (dantrolene sodium) for the treatment of organophosphate exposure; PEMFEXY™ (pemetrexed for injection) for lung cancer; and EA-114 (fulvestrant) for breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
20,245 |
87,045 |
| Total Sell Value |
$0 |
$0 |
$300,027 |
$1,741,115 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
2 |
7 |
| End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Braunstein Douglas L |
Director |
– • – |
2019-10-10 |
4 |
AS |
$60.16 |
$471,002 |
I/I |
(7,829) |
796,077 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-08 |
4 |
AS |
$60.03 |
$93,520 |
I/I |
(1,558) |
803,906 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-10-07 |
4 |
AS |
$60.11 |
$294,600 |
I/I |
(4,901) |
805,464 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-09-17 |
4 |
AS |
$60.00 |
$6,000 |
I/I |
(100) |
810,365 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-09-12 |
4 |
AS |
$60.07 |
$12,014 |
I/I |
(200) |
810,465 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-09-11 |
4 |
AS |
$60.06 |
$66,785 |
I/I |
(1,112) |
810,665 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-05-10 |
4 |
S |
$56.14 |
$5,614,000 |
I/I |
(100,000) |
811,777 |
|
- |
|
| Braunstein Douglas L |
Director |
– • – |
2019-05-09 |
4 |
S |
$57.95 |
$3,431,973 |
I/I |
(59,223) |
911,777 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2019-04-01 |
4 |
AS |
$50.15 |
$1,252,496 |
D/D |
(24,975) |
1,500,202 |
|
- |
|
| Flaum Sander A |
Director |
– • – |
2019-03-05 |
4 |
D |
$48.89 |
$9,974 |
D/D |
(204) |
13,510 |
|
- |
|
| Flaum Sander A |
Director |
– • – |
2019-03-05 |
4 |
OE |
$4.04 |
$9,454 |
D/D |
2,340 |
13,714 |
|
- |
|
| Ratoff Steven B |
Director |
– • – |
2019-03-04 |
4 |
OE |
$4.04 |
$9,454 |
D/D |
2,340 |
18,004 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2019-03-01 |
4 |
AS |
$50.51 |
$1,250,015 |
D/D |
(24,428) |
1,525,177 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2019-02-01 |
4 |
AS |
$41.52 |
$1,249,831 |
D/D |
(30,085) |
1,549,605 |
|
- |
|
| Pernock David |
Pres. & Chief Comm. Officer |
• – – |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
20,900 |
31,008 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
61,300 |
1,579,690 |
|
- |
|
| Meyers Peter A. |
Chief Financial Officer |
• – – |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
19,300 |
26,400 |
|
- |
|
| Hepner Adrian |
EVP and Chief Medical Officer |
• – – |
2019-01-23 |
4 |
A |
$0.00 |
$0 |
D/D |
19,000 |
27,229 |
|
- |
|
| Pernock David |
Pres. & Chief Comm. Officer |
• – – |
2019-01-07 |
4 |
D |
$41.33 |
$35,461 |
D/D |
(858) |
10,108 |
|
- |
|
| Meyers Peter A. |
Chief Financial Officer |
• – – |
2019-01-07 |
4 |
D |
$41.33 |
$24,798 |
D/D |
(600) |
7,100 |
|
- |
|
| Hepner Adrian |
EVP and Chief Medical Officer |
• – – |
2019-01-07 |
4 |
D |
$41.33 |
$31,865 |
D/D |
(771) |
8,229 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2019-01-03 |
4 |
AS |
$39.04 |
$651,058 |
D/D |
(16,569) |
1,518,390 |
|
- |
|
| Tarriff Scott |
CEO |
• • • |
2019-01-02 |
4 |
AS |
$39.30 |
$595,705 |
D/D |
(15,000) |
1,534,959 |
|
- |
|
| Tarriff Scott |
CEO |
• • – |
2018-06-28 |
4 |
OE |
$4.04 |
$504,208 |
D/D |
124,804 |
1,549,959 |
|
- |
|
| Tarriff Scott |
CEO |
• • – |
2018-03-30 |
4 |
D |
$52.69 |
$3,050,488 |
D/D |
(57,895) |
1,425,155 |
|
- |
|
199 Records found
|
|
Page 4 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.11 (2.71%) 
